|
Name |
Bacillomycin
|
| Molecular Formula | C45H68N10O15 | |
| IUPAC Name* |
3-[(3R,6R,9S,16S,19R,22S,25S)-3,9-bis(2-amino-2-oxoethyl)-16-[(1R)-1-hydroxyethyl]-19-(hydroxymethyl)-6-[(4-hydroxyphenyl)methyl]-13-octyl-2,5,8,11,15,18,21,24-octaoxo-1,4,7,10,14,17,20,23-octazabicyclo[23.3.0]octacosan-22-yl]propanoic acid
|
|
| SMILES |
CCCCCCCCC1CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)O)CO)CCC(=O)O)CC(=O)N)CC3=CC=C(C=C3)O)CC(=O)N
|
|
| InChI |
InChI=1S/C45H68N10O15/c1-3-4-5-6-7-8-10-26-20-36(61)49-30(21-34(46)59)41(66)51-29(19-25-12-14-27(58)15-13-25)40(65)52-31(22-35(47)60)45(70)55-18-9-11-33(55)43(68)50-28(16-17-37(62)63)39(64)53-32(23-56)42(67)54-38(24(2)57)44(69)48-26/h12-15,24,26,28-33,38,56-58H,3-11,16-23H2,1-2H3,(H2,46,59)(H2,47,60)(H,48,69)(H,49,61)(H,50,68)(H,51,66)(H,52,65)(H,53,64)(H,54,67)(H,62,63)/t24-,26?,28+,29-,30+,31-,32-,33+,38+/m1/s1
|
|
| InChIKey |
VLKSXJAPRDAENT-OWGHDAAGSA-N
|
|
| Synonyms |
Bacillomycin; 76012-17-4; Q4838953
|
|
| CAS | 76012-17-4 | |
| PubChem CID | 3086051 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 989.1 | ALogp: | -1.1 |
| HBD: | 13 | HBA: | 15 |
| Rotatable Bonds: | 18 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 408.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 70 | QED Weighted: | 0.064 |
| Caco-2 Permeability: | -6.754 | MDCK Permeability: | 0.00001280 |
| Pgp-inhibitor: | 0.2 | Pgp-substrate: | 1 |
| Human Intestinal Absorption (HIA): | 0.988 | 20% Bioavailability (F20%): | 1 |
| 30% Bioavailability (F30%): | 1 |
| Blood-Brain-Barrier Penetration (BBB): | 0.021 | Plasma Protein Binding (PPB): | 44.12% |
| Volume Distribution (VD): | 0.327 | Fu: | 43.92% |
| CYP1A2-inhibitor: | 0 | CYP1A2-substrate: | 0.001 |
| CYP2C19-inhibitor: | 0.009 | CYP2C19-substrate: | 0.019 |
| CYP2C9-inhibitor: | 0.059 | CYP2C9-substrate: | 0.17 |
| CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.018 |
| CYP3A4-inhibitor: | 0.011 | CYP3A4-substrate: | 0.001 |
| Clearance (CL): | 1.161 | Half-life (T1/2): | 0.609 |
| hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.571 |
| Drug-inuced Liver Injury (DILI): | 0.033 | AMES Toxicity: | 0.004 |
| Rat Oral Acute Toxicity: | 0.237 | Maximum Recommended Daily Dose: | 0.081 |
| Skin Sensitization: | 0.048 | Carcinogencity: | 0.03 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.002 |
| Respiratory Toxicity: | 0.003 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001950 | ![]() |
0.783 | D0M3FJ | ![]() |
0.459 | ||
| ENC003247 | ![]() |
0.778 | D00GNJ | ![]() |
0.448 | ||
| ENC003171 | ![]() |
0.776 | D09PZZ | ![]() |
0.445 | ||
| ENC002094 | ![]() |
0.758 | D02SBQ | ![]() |
0.442 | ||
| ENC003283 | ![]() |
0.721 | D06WKA | ![]() |
0.437 | ||
| ENC005271 | ![]() |
0.545 | D0N4OW | ![]() |
0.427 | ||
| ENC005273 | ![]() |
0.534 | D0U7SH | ![]() |
0.424 | ||
| ENC005275 | ![]() |
0.528 | D0J7XL | ![]() |
0.418 | ||
| ENC005274 | ![]() |
0.515 | D0D8XY | ![]() |
0.417 | ||
| ENC001088 | ![]() |
0.509 | D0P4VX | ![]() |
0.411 | ||